Geneva Capital Management LLC Has $79.76 Million Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geneva Capital Management LLC decreased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 865,582 shares of the medical instruments supplier's stock after selling 12,263 shares during the period. LeMaitre Vascular accounts for about 1.4% of Geneva Capital Management LLC's investment portfolio, making the stock its 24th largest holding. Geneva Capital Management LLC owned 3.85% of LeMaitre Vascular worth $79,755,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its stake in shares of LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after buying an additional 4,330 shares in the last quarter. Townsquare Capital LLC grew its holdings in LeMaitre Vascular by 38.0% during the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier's stock worth $4,454,000 after acquiring an additional 13,210 shares during the period. Barclays PLC raised its position in LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after acquiring an additional 29,180 shares in the last quarter. Compass Planning Associates Inc acquired a new stake in LeMaitre Vascular in the 4th quarter valued at about $567,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in LeMaitre Vascular by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock valued at $17,789,000 after acquiring an additional 11,395 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

LeMaitre Vascular Trading Up 0.6 %

NASDAQ LMAT traded up $0.51 during trading on Monday, reaching $81.88. The company's stock had a trading volume of 283,409 shares, compared to its average volume of 141,989. The stock has a market capitalization of $1.85 billion, a PE ratio of 44.74, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58. The business has a 50-day moving average price of $96.29 and a 200-day moving average price of $94.95.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million during the quarter, compared to analysts' expectations of $55.99 million. As a group, analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date is Thursday, March 13th. LeMaitre Vascular's dividend payout ratio is 41.24%.

Analysts Set New Price Targets

LMAT has been the topic of a number of research reports. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital upped their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.